<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18060">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871778</url>
  </required_header>
  <id_info>
    <org_study_id>PS-G202</org_study_id>
    <secondary_id>2015-004917-26</secondary_id>
    <nct_id>NCT02871778</nct_id>
  </id_info>
  <brief_title>Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia</brief_title>
  <acronym>CLEAN-PCD</acronym>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation in Subjects With Primary Ciliary Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parion Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of treatment with VX-371, and the effect of VX-371 on
      quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From the first dose of study drug to 28 days after the last dose in the same period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in percent predicted FEV1</measure>
    <time_frame>Baseline, after 28 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL), as determined by mean change in QOL-PCD and SGRQ (St. George's Respiratory Questionnaire) scores.</measure>
    <time_frame>Baseline, after 28 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Primary Ciliary Dyskinesia</condition>
  <arm_group>
    <arm_group_label>VX-371 in Hypertonic Saline, then Hypertonic Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: VX-371 in Hypertonic Saline
Treatment Period 2: Hypertonic Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic Saline, then VX-371 in Hypertonic Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: Hypertonic Saline
Treatment Period 2: VX-371 in Hypertonic Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-371, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: VX-371
Treatment Period 2: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then VX-371</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: Placebo
Treatment Period 2: VX-371</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-371</intervention_name>
    <arm_group_label>VX-371 in Hypertonic Saline, then Hypertonic Saline</arm_group_label>
    <arm_group_label>Hypertonic Saline, then VX-371 in Hypertonic Saline</arm_group_label>
    <arm_group_label>VX-371, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then VX-371</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <arm_group_label>VX-371 in Hypertonic Saline, then Hypertonic Saline</arm_group_label>
    <arm_group_label>Hypertonic Saline, then VX-371 in Hypertonic Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.17% saline)</intervention_name>
    <arm_group_label>VX-371, then Placebo</arm_group_label>
    <arm_group_label>Placebo, then VX-371</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of PCD

          -  Subjects with percent predicted FEV1 of â‰¥40 to &lt;90 percentage points

          -  Non-smoker for at least 90 days prior to the Screening Visit and less than a 5
             pack-year lifetime history of smoking

          -  Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1

          -  If currently using daily inhaled HS, must be able to discontinue its use for the
             duration of the study.

          -  If taking daily chronic or chronic cycling antibiotics, has been on a consistent
             regimen for at least 4 months prior to the Screening Visit.

          -  Clinically stable (as deemed by the investigator) for at least 14 days prior to the
             Screening Visit

          -  Female subjects of childbearing potential must have a negative serum pregnancy test
             at the Screening Visit. Subjects of childbearing potential and who are sexually
             active must meet the contraception requirements.

        Exclusion Criteria:

          -  Diagnosis of CF based on results of sweat chloride or nasal transepithelial potential
             difference (NPD) tests or presence of 2 CF-causing genetic mutations in CFTR gene.

          -  History of any organ transplantation or lung resection or chest wall surgery of such
             severity that it has an impact on pulmonary function.

          -  Significant congenital heart defects, other than a laterality defect, at the
             discretion of the investigator

          -  Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome).

          -  Inability to withhold short-acting bronchodilator use for 4 hours prior to clinic
             visit.

          -  Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs

          -  Symptoms of acute upper or lower respiratory tract infection, acute pulmonary
             exacerbation, or treatment or was treated with systemic antibiotics for ear or sinus
             disease within 14 days before Day 1 (topical otic antibiotics allowed).

          -  History of significant intolerance to inhaled HS

          -  Pregnant and/or nursing females

          -  Any clinically significant laboratory abnormalities

          -  History of chronic B. cepacia complex or M. abscessus or M. avium

          -  Surgery that required general anesthesia and hospitalization within 3 months of Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashley Simmons</last_name>
    <phone>919-313-1210</phone>
    <email>asimmons@parion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabka-Zdroj</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>August 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Kartagener Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
